BLAINTRAVESICALSOLUTION
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
ANKTIVA (nogapendekin alfa inbakicept-pmln) by Immunitas Therapeutics is inbakicept-pmln is an il-15 receptor agonist. First approved in 2024.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANKTIVA (nogapendekin alfa inbakicept-pmln) is an IL-15 receptor agonist approved for intravesical administration in bladder cancer. It activates NK cells, CD8+ T cells, and memory T cells without expanding immunosuppressive Tregs, enhancing anti-tumor immunity when combined with BCG. The drug represents a novel immunotherapy approach targeting the IL-15 signaling pathway to overcome bladder cancer resistance.
Growth
Early-stage growth product with limited competitive pressure (30% score) presents opportunity for team expansion and market-building roles in uro-oncology.
Mechanism of Action
inbakicept-pmln is an IL-15 receptor agonist. IL-15 signals through a heterotrimeric receptor that is composed of the common gamma chain (γc) subunit, the beta chain (βc) subunit, and the IL-15-specific alpha subunit, IL-15 receptor α. IL-15 is trans -presented by the IL-15 receptor α to the shared…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer
Started May 2026
0NMIBC
A Study to Assess Anktiva in Patients With Long Covid-19.
Started Nov 2025
20 enrolled
Long COVID
A Study to Examine Anktiva for the Treatment of COVID-19.
Started Sep 2025
40 enrolled
Long COVIDLong COVID SyndromeLong Covid 19
Worked on ANKTIVA at Immunitas Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.